{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T10:13:32Z","timestamp":1770372812083,"version":"3.49.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:00:00Z","timestamp":1767916800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:00:00Z","timestamp":1767916800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS PharmSciTech"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Clofazimine (CFZ), an old and highly lipophilic antimycobacterial drug, is a second-line agent for the treatment of multi-drug-resistant tuberculosis (MDR-TB) and has demonstrated antitubercular efficacy when administered to the lung as different inhalation dry powder formulations. While its efficacy has been established, consensus has not been identified regarding the lung dose, pharmacokinetic (PK) properties, and biodistribution following inhalation. This study aimed to establish the biodistribution and inhaled PK of CFZ dry powder inhalation (DPI) formulation after single and multiple doses in healthy mice. Following a single low or high inhaled dose in healthy mice, lung concentrations of CFZ were\u2009~\u200920 folds higher than the corresponding plasma concentrations. Administering eight consecutive inhaled doses (twice weekly) maintained high and sustained lung concentrations (28 to 69 times higher than plasma concentrations), remaining significantly above the minimum inhibitory concentration (MIC: 0.6 \u2013 2.0\u00a0\u03bcg\/mL) of the free drug. Notably, CFZ concentrations in the lungs and plasma showed no discernable elimination phase up to four weeks post-dosing, with prolonged retention. Biodistribution studies indicated preferential CFZ retention in lung and spleen tissue following both single and multiple inhaled doses. In conclusion, these results suggest the novel dry powder inhaled CFZ formulation can produce high therapeutic concentration in lung tissues for extended periods of time after single and multiple doses, thereby, underscoring the potential of using inhaled CFZ as the treatment of MDR-TB.<\/jats:p>\n                  <jats:p>\n                    <jats:bold>Graphical Abstract<\/jats:bold>\n                  <\/jats:p>","DOI":"10.1208\/s12249-025-03301-6","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T19:52:23Z","timestamp":1767988343000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacokinetics of Inhaled Clofazimine Dry Powder in Healthy Mice"],"prefix":"10.1208","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-9448-0457","authenticated-orcid":false,"given":"Prachi","family":"Agrawal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4392-4895","authenticated-orcid":false,"given":"Kinnari","family":"Arte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5512-5579","authenticated-orcid":false,"given":"Justin A.","family":"Tolman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,9]]},"reference":[{"issue":"4","key":"3301_CR1","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.cmi.2020.06.004","volume":"27","author":"M Gao","year":"2021","unstructured":"Gao M, Gao J, Xie L, Wu G, Chen W, Chen Y, et al. Early outcome and safety of bedaquiline-containing regimens for treatment of MDR-and XDR-TB in China: a multicentre study. Clin Microbiol Infect. 2021;27(4):597\u2013602.","journal-title":"Clin Microbiol Infect"},{"key":"3301_CR2","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.ijid.2021.07.038","volume":"110","author":"J Li","year":"2021","unstructured":"Li J, Yang G, Cai Q, Wang Y, Xu Y, Zhang R, et al. Safety, efficacy, and serum concentration monitoring of bedaquiline in Chinese patients with multidrug-resistant tuberculosis. Int J Infect Dis. 2021;110:179\u201386.","journal-title":"Int J Infect Dis"},{"key":"3301_CR3","doi-asserted-by":"crossref","unstructured":"Nguyen TMP, Le THM, Merle CSC, et al. Effectiveness and safety of bedaquiline-based, modified all-oral 9-11-month treatment regimen for rifampicin-resistant tuberculosis in Vietnam. Int J Infect Dis. 2023;126:148\u201354.","DOI":"10.1016\/j.ijid.2022.11.007"},{"key":"3301_CR4","doi-asserted-by":"crossref","unstructured":"Ranjan R, Devireddy VSR. Prospects of inhalable formulations of conventionally administered repurposed drugs for adjunctive treatment of drug-resistant tuberculosis: supporting evidence from clinical trials and cohort studies. J Aerosol Med Pulm Drug Deliv. 2025;38(4):149\u201367.","DOI":"10.1089\/jamp.2024.0051"},{"issue":"2","key":"3301_CR5","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.cmi.2018.07.012","volume":"25","author":"H Duan","year":"2019","unstructured":"Duan H, Chen X, Li Z, Pang Y, Jing W, Liu P, et al. Clofazimine improves clinical outcomes in multidrug-resistant tuberculosis: a randomized controlled trial. Clin Microbiol Infect. 2019;25(2):190\u20135.","journal-title":"Clin Microbiol Infect"},{"issue":"2","key":"3301_CR6","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.cmi.2018.11.010","volume":"25","author":"CG Lange","year":"2019","unstructured":"Lange CG, Chesov D, Heyckendorf J. Clofazimine for the treatment of multidrug-resistant tuberculosis. Clin Microbiol Infect. 2019;25(2):128\u201330.","journal-title":"Clin Microbiol Infect"},{"key":"3301_CR7","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/j.biopha.2018.06.023","volume":"105","author":"R Mirnejad","year":"2018","unstructured":"Mirnejad R, Asadi A, Khoshnood S, Mirzaei H, Heidary M, Fattorini L, et al. Clofazimine: a useful antibiotic for drug-resistant tuberculosis. Biomed Pharmacother. 2018;105:1353\u20139.","journal-title":"Biomed Pharmacother"},{"issue":"1\u20132","key":"3301_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.micinf.2022.105020","volume":"25","author":"M-G Wang","year":"2023","unstructured":"Wang M-G, Liu X-M, Wu S-Q, He J-Q. Impacts of clofazimine on the treatment outcomes of drug-resistant tuberculosis. Microbes Infect. 2023;25(1\u20132):105020.","journal-title":"Microbes Infect"},{"issue":"11","key":"3301_CR9","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1111\/j.1469-0691.2011.03716.x","volume":"18","author":"HB Xu","year":"2012","unstructured":"Xu HB, Jiang RH, Xiao HP. Clofazimine in the treatment of multidrug-resistant tuberculosis. Clin Microbiol Infect. 2012;18(11):1104\u201310.","journal-title":"Clin Microbiol Infect"},{"key":"3301_CR10","doi-asserted-by":"publisher","first-page":"213594","DOI":"10.1016\/j.bioadv.2023.213594","volume":"154","author":"K Jadhav","year":"2023","unstructured":"Jadhav K, Jhilta A, Singh R, Ray E, Sharma N, Shukla R, et al. Clofazimine nanoclusters show high efficacy in experimental TB with amelioration in paradoxical lung inflammation. Biomater Adv. 2023;154:213594.","journal-title":"Biomater Adv"},{"issue":"2","key":"3301_CR11","first-page":"72","volume":"2","author":"ML Aznar","year":"2018","unstructured":"Aznar ML, Brode SK, Mehrabi M, Marras TK. Safety and effectiveness of clofazimine in nontuberculous mycobacterial lung disease. Can J Respir Crit Care Sleep Med. 2018;2(2):72\u20137.","journal-title":"Can J Respir Crit Care Sleep Med"},{"key":"3301_CR12","doi-asserted-by":"publisher","first-page":"102268","DOI":"10.1016\/j.tube.2022.102268","volume":"137","author":"D Sriram","year":"2022","unstructured":"Sriram D, Wahi R, Maggioncalda EC, Panthi CM, Lamichhane G. Clofazimine as a comparator for preclinical efficacy evaluations of experimental therapeutics against pulmonary M. abscessus infection in mice. Tuberculosis. 2022;137:102268.","journal-title":"Tuberculosis"},{"issue":"2","key":"3301_CR13","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1093\/jac\/dkr444","volume":"67","author":"MC Cholo","year":"2012","unstructured":"Cholo MC, Steel HC, Fourie PB, Germishuizen WA, Anderson R. Clofazimine: current status and future prospects. J Antimicrob Chemother. 2012;67(2):290\u20138.","journal-title":"J Antimicrob Chemother"},{"key":"3301_CR14","unstructured":"Morrison NE, Marley GM. The mode of action of clofazimine DNA binding studies. Int J Lepr Other Mycobact Dis. 1976;44(1-2):133\u20134."},{"issue":"2","key":"3301_CR15","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1093\/jac\/44.2.209","volume":"44","author":"H Steel","year":"1999","unstructured":"Steel H, Matlola N, Anderson R. Inhibition of potassium transport and growth of mycobacteria exposed to clofazimine and B669 is associated with a calcium-independent increase in microbial phospholipase A2 activity. J Antimicrob Chemother. 1999;44(2):209\u201316.","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"3301_CR16","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1164\/rccm.201001-0077OC","volume":"182","author":"A Van Deun","year":"2010","unstructured":"Van Deun A, Maug AKJ, Salim MAH, Das PK, Sarker MR, Daru P, et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med. 2010;182(5):684\u201392.","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"3301_CR17","doi-asserted-by":"publisher","first-page":"10276","DOI":"10.1074\/jbc.M110.200501","volume":"286","author":"T Yano","year":"2011","unstructured":"Yano T, Kassovska-Bratinova S, Teh JS, Winkler J, Sullivan K, Isaacs A, et al. Reduction of Clofazimine by Mycobacterial Type 2 NADH:Quinone Oxidoreductase: A pathway for the generation of bactericidal levels of reactive oxygen species*. J Biol Chem. 2011;286(12):10276\u201387.","journal-title":"J Biol Chem"},{"issue":"2","key":"3301_CR18","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1093\/jac\/dkw426","volume":"72","author":"MC Cholo","year":"2016","unstructured":"Cholo MC, Mothiba MT, Fourie B, Anderson R. Mechanisms of action and therapeutic efficacies of the lipophilic antimycobacterial agents clofazimine and bedaquiline. J Antimicrob Chemother. 2016;72(2):338\u201353.","journal-title":"J Antimicrob Chemother"},{"key":"3301_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2021.102058","volume":"70","author":"HOI Pfaeffle","year":"2021","unstructured":"Pfaeffle HOI, Alameer RM, Marshall MH, Houpt ER, Albon DP, Heysell SK. Clofazimine for treatment of multidrug-resistant non-tuberculous mycobacteria. Pulm Pharmacol Ther. 2021;70:102058.","journal-title":"Pulm Pharmacol Ther"},{"issue":"1","key":"3301_CR20","first-page":"9","volume":"55","author":"Z Schaad-Lanyi","year":"1987","unstructured":"Schaad-Lanyi Z, Dieterle W, Dubois JP, Theobald W, Vischer W. Pharmacokinetics of clofazimine in healthy volunteers. Int J Lepr Other Mycobact Dis. 1987;55(1):9\u201315.","journal-title":"Int J Lepr Other Mycobact Dis"},{"key":"3301_CR21","doi-asserted-by":"crossref","unstructured":"McGuffin SA, Pottinger PS, Harnisch JP. Clofazimine in nontuberculous mycobacterial infections: a growing niche. OFID. 2017;4(3):1\u20137.","DOI":"10.1093\/ofid\/ofx147"},{"issue":"8","key":"3301_CR22","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.5588\/ijtld.12.0144","volume":"17","author":"M Gopal","year":"2013","unstructured":"Gopal M, Padayatchi N, Metcalfe JZ, O\u2019Donnell MR. Systematic review of clofazimine for the treatment of drug-resistant tuberculosis. Int J Tuberc Lung Dis. 2013;17(8):1001\u20137.","journal-title":"Int J Tuberc Lung Dis"},{"key":"3301_CR23","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.ejpb.2023.04.009","volume":"187","author":"K Yamanouchi","year":"2023","unstructured":"Yamanouchi K, Ishimaru T, Kakuno T, Takemoto Y, Kawatsu S, Kondo K, et al. Improvement and characterization of oral absorption behavior of clofazimine by SNEDDS: quantitative evaluation of extensive lymphatic transport. Eur J Pharm Biopharm. 2023;187:141\u201355.","journal-title":"Eur J Pharm Biopharm"},{"issue":"2","key":"3301_CR24","doi-asserted-by":"publisher","first-page":"74","DOI":"10.2165\/00003088-198916020-00002","volume":"16","author":"MR Holdiness","year":"1989","unstructured":"Holdiness MR. Clinical pharmacokinetics of clofazimine. Clin Pharmacokinet. 1989;16(2):74\u201385.","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"3301_CR25","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.tube.2004.04.001","volume":"84","author":"DE Nix","year":"2004","unstructured":"Nix DE, Adam RD, Auclair B, Krueger TS, Godo PG, Peloquin CA. Pharmacokinetics and relative bioavailability of clofazimine in relation to food, orange juice and antacid. Tuberculosis. 2004;84(6):365\u201373.","journal-title":"Tuberculosis"},{"key":"3301_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0047494","author":"J Baik","year":"2012","unstructured":"Baik J, Rosania GR. Macrophages sequester clofazimine in an intracellular liquid crystal-like supramolecular organization. PLoS One. 2012. https:\/\/doi.org\/10.1371\/journal.pone.0047494.","journal-title":"PLoS One"},{"issue":"4","key":"3301_CR27","doi-asserted-by":"publisher","first-page":"591","DOI":"10.3109\/03602539508994208","volume":"27","author":"R O\u2019connor","year":"1995","unstructured":"O\u2019connor R, O\u2019sullivan J, O\u2019kennedy R. The pharmacology, metabolism, and chemistry of clofazimine. Drug Metab Rev. 1995;27(4):591\u2013614.","journal-title":"Drug Metab Rev"},{"issue":"9","key":"3301_CR28","doi-asserted-by":"publisher","first-page":"e00186","DOI":"10.1128\/aac.00186-22","volume":"66","author":"AD Brunaugh","year":"2022","unstructured":"Brunaugh AD, Walz A, Warnken Z, Pearce C, Munoz Gutierrez J, Koleng JJ, et al. Respirable clofazimine particles produced by air jet milling technique are efficacious in treatment of BALB\/c mice with chronic Mycobacterium tuberculosis infection. Antimicrob Agents Chemother. 2022;66(9):e00186-22.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"3301_CR29","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.chest.2017.04.175","volume":"152","author":"SL Martiniano","year":"2017","unstructured":"Martiniano SL, Wagner BD, Levin A, Nick JA, Sagel SD, Daley CL. Safety and effectiveness of clofazimine for primary and refractory nontuberculous mycobacterial infection. Chest. 2017;152(4):800\u20139.","journal-title":"Chest"},{"issue":"11","key":"3301_CR30","doi-asserted-by":"publisher","first-page":"3269","DOI":"10.1093\/jac\/dkaa310","volume":"75","author":"MT Abdelwahab","year":"2020","unstructured":"Abdelwahab MT, Wasserman S, Brust JCM, Gandhi NR, Meintjes G, Everitt D, et al. Clofazimine pharmacokinetics in patients with TB: dosing implications. J Antimicrob Chemother. 2020;75(11):3269\u201377.","journal-title":"J Antimicrob Chemother"},{"key":"3301_CR31","doi-asserted-by":"publisher","first-page":"1100488","DOI":"10.3389\/fphar.2023.1100488","volume":"14","author":"JAM Stadler","year":"2023","unstructured":"Stadler JAM, Maartens G, Meintjes G, Wasserman S. Clofazimine for the treatment of tuberculosis. Front Pharmacol. 2023;14:1100488.","journal-title":"Front Pharmacol"},{"issue":"5","key":"3301_CR32","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1016\/j.chest.2023.11.038","volume":"165","author":"SMH Zweijpfenning","year":"2024","unstructured":"Zweijpfenning SMH, Aarnoutse R, Boeree MJ, Magis-Escurra C, Stemkens R, Geurts B, et al. Safety and Efficacy of Clofazimine as an Alternative for Rifampicin in Mycobacterium avium Complex Pulmonary Disease Treatment: Outcomes of a Randomized Trial. Chest. 2024;165(5):1082\u201392.","journal-title":"Chest"},{"key":"3301_CR33","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02445-2016","author":"M Dalcolmo","year":"2017","unstructured":"Dalcolmo M, Gayoso R, Sotgiu G, D\u2019Ambrosio L, Rocha JL, Borga L, et al. Effectiveness and safety of clofazimine in multidrug-resistant tuberculosis: a nationwide report from Brazil. Eur Respir J. 2017. https:\/\/doi.org\/10.1183\/13993003.02445-2016.","journal-title":"Eur Respir J"},{"issue":"1","key":"3301_CR34","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ejpb.2013.10.019","volume":"86","author":"M Hoppentocht","year":"2014","unstructured":"Hoppentocht M, Hagedoorn P, Frijlink HW, de Boer AH. Developments and strategies for inhaled antibiotic drugs in tuberculosis therapy: a critical evaluation. Eur J Pharm Biopharm. 2014;86(1):23\u201330.","journal-title":"Eur J Pharm Biopharm"},{"key":"3301_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2020.101805","volume":"58","author":"RR de Castro","year":"2020","unstructured":"de Castro RR, Todaro V, da Silva LCRP, Simon A, do Carmo FA, de Sousa VP, et al. Development of inhaled formulation of modified clofazimine as an alternative to treatment of tuberculosis. J Drug Deliv Sci Technol. 2020;58:101805.","journal-title":"J Drug Deliv Sci Technol"},{"key":"3301_CR36","volume":"39","author":"J Raaijmakers","year":"2024","unstructured":"Raaijmakers J, Aarnoutse RE, Brake LT, Stemkens R, Wertheim HFl, Hoefsloot W, et al. Inhaled clofazimine adminsitration increases antimycobacterial effect compared to oral administration in a hollow-fibre system. J Glob Antimicrob Resist. 2024;39:58.","journal-title":"J Glob Antimicrob Resist"},{"issue":"6","key":"3301_CR37","doi-asserted-by":"publisher","first-page":"754","DOI":"10.3390\/ph17060754","volume":"17","author":"DS Rongala","year":"2024","unstructured":"Rongala DS, Patil SM, Kunda NK. Design of experiment (DoE) approach for developing inhalable PLGA microparticles loaded with Clofazimine for tuberculosis treatment. Pharmaceuticals. 2024;17(6):754.","journal-title":"Pharmaceuticals"},{"issue":"1","key":"3301_CR38","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.ejps.2008.02.008","volume":"34","author":"J Kaur","year":"2008","unstructured":"Kaur J, Muttil P, Verma RK, Kumar K, Yadav AB, Sharma R, et al. A hand-held apparatus for \u201cnose-only\u201d exposure of mice to inhalable microparticles as a dry powder inhalation targeting lung and airway macrophages. Eur J Pharm Sci. 2008;34(1):56\u201365.","journal-title":"Eur J Pharm Sci"},{"issue":"2","key":"3301_CR39","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1128\/AAC.01897-12","volume":"57","author":"RK Verma","year":"2013","unstructured":"Verma RK, Germishuizen WA, Motheo MP, Agrawal AK, Singh AK, Mohan M, et al. Inhaled microparticles containing clofazimine are efficacious in treatment of experimental tuberculosis in mice. Antimicrob Agents Chemother. 2013;57(2):1050\u20132.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"3301_CR40","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.jcf.2019.05.013","volume":"18","author":"B Banaschewski","year":"2019","unstructured":"Banaschewski B, Verma D, Pennings LJ, Zimmerman M, Ye Q, Gadawa J, et al. Clofazimine inhalation suspension for the aerosol treatment of pulmonary nontuberculous mycobacterial infections. J Cyst Fibros. 2019;18(5):714\u201320.","journal-title":"J Cyst Fibros"},{"key":"3301_CR41","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.ejpb.2023.05.017","volume":"188","author":"D Qi","year":"2023","unstructured":"Qi D, Jia B, Peng H, He J, Pi J, Guo P, et al. Baicalin\/ambroxol hydrochloride combined dry powder inhalation formulation targeting lung delivery for treatment of idiopathic pulmonary fibrosis: fabrication, characterization, pharmacokinetics, and pharmacodynamics. Eur J Pharm Biopharm. 2023;188:243\u201353.","journal-title":"Eur J Pharm Biopharm"},{"issue":"8","key":"3301_CR42","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1081\/DDC-120006431","volume":"28","author":"AS Narang","year":"2002","unstructured":"Narang AS, Srivastava AK. Evaluation of solid dispersions of clofazimine. Drug Dev Ind Pharm. 2002;28(8):1001\u201313.","journal-title":"Drug Dev Ind Pharm"},{"issue":"3","key":"3301_CR43","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1021\/acsinfecdis.4c00767","volume":"11","author":"K Jadhav","year":"2025","unstructured":"Jadhav K, Jhilta A, Singh R, Negi S, Sharma S, Shukla R, et al. Pharmacokinetic and pharmacodynamics of clofazimine nano-in-microparticles: enhanced brain delivery and CNS tuberculosis amelioration via intranasal administration. ACS Infect Dis. 2025;11(3):665\u201375.","journal-title":"ACS Infect Dis"},{"key":"3301_CR44","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.jconrel.2024.03.013","volume":"369","author":"JE Campos Pacheco","year":"2024","unstructured":"Campos Pacheco JE, Yalovenko T, Riaz A, Kotov N, Davids C, Persson A, et al. Inhalable porous particles as dual micro-nano carriers demonstrating efficient lung drug delivery for treatment of tuberculosis. J Control Release. 2024;369:231\u201350.","journal-title":"J Control Release"},{"key":"3301_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejpb.2021.02.011","volume":"162","author":"P Khadka","year":"2021","unstructured":"Khadka P, Sinha S, Tucker IG, Dummer J, Hill PC, Katare R, et al. Pharmacokinetics of rifampicin after repeated intra-tracheal administration of amorphous and crystalline powder formulations to Sprague Dawley rats. Eur J Pharm Biopharm. 2021;162:1\u201311.","journal-title":"Eur J Pharm Biopharm"},{"key":"3301_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2024.124031","volume":"655","author":"H Paliwal","year":"2024","unstructured":"Paliwal H, Nakpheng T, Kumar Paul P, Prem Ananth K, Srichana T. Development of a self-microemulsifying drug delivery system to deliver delamanid via a pressurized metered dose inhaler for treatment of multi-drug resistant pulmonary tuberculosis. Int J Pharm. 2024;655:124031.","journal-title":"Int J Pharm"},{"key":"3301_CR47","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.ejpb.2016.07.014","volume":"107","author":"T Parumasivam","year":"2016","unstructured":"Parumasivam T, Chan JGY, Pang A, Quan DH, Triccas JA, Britton WJ, et al. In vitro evaluation of novel inhalable dry powders consisting of thioridazine and rifapentine for rapid tuberculosis treatment. Eur J Pharm Biopharm. 2016;107:205\u201314.","journal-title":"Eur J Pharm Biopharm"},{"issue":"1","key":"3301_CR48","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.ejpb.2012.09.018","volume":"83","author":"C Rundfeldt","year":"2013","unstructured":"Rundfeldt C, Steckel H, Scherliess H, Wyska E, Wla\u017a P. Inhalable highly concentrated itraconazole nanosuspension for the treatment of bronchopulmonary aspergillosis. Eur J Pharm Biopharm. 2013;83(1):44\u201353.","journal-title":"Eur J Pharm Biopharm"},{"issue":"3","key":"3301_CR49","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.ejpb.2012.11.005","volume":"83","author":"A Schoubben","year":"2013","unstructured":"Schoubben A, Blasi P, Marenzoni ML, Barberini L, Giovagnoli S, Cirotto C, et al. Capreomycin supergenerics for pulmonary tuberculosis treatment: preparation, in vitro, and in vivo characterization. Eur J Pharm Biopharm. 2013;83(3):388\u201395.","journal-title":"Eur J Pharm Biopharm"},{"issue":"3","key":"3301_CR50","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01157-23","volume":"68","author":"S Salillas","year":"2024","unstructured":"Salillas S, Raaijmakers J, Aarnoutse Rob E, Svensson Elin M, Asouit K, van den Hombergh E, et al. Clofazimine as a substitute for rifampicin improves efficacy of Mycobacterium avium pulmonary disease treatment in the hollow-fiber model. Antimicrob Agents Chemother. 2024;68(3):e01157-e1223.","journal-title":"Antimicrob Agents Chemother"},{"key":"3301_CR51","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2020.626216","author":"JM Lee","year":"2021","unstructured":"Lee JM, Park J, Choi S, Jhun BW, Kim S-Y, Jo K-W, et al. A clofazimine-containing regimen confers improved treatment outcomes in macrophages and in a murine model of chronic progressive pulmonary infection caused by the Mycobacterium avium complex. Front Microbiol. 2021. https:\/\/doi.org\/10.3389\/fmicb.2020.626216.","journal-title":"Front Microbiol"},{"issue":"6","key":"3301_CR52","doi-asserted-by":"publisher","first-page":"3042","DOI":"10.1128\/AAC.00260-15","volume":"59","author":"RV Swanson","year":"2015","unstructured":"Swanson RV, Adamson J, Moodley C, Ngcobo B, Ammerman NC, Dorasamy A, et al. Pharmacokinetics and pharmacodynamics of clofazimine in a mouse model of tuberculosis. Antimicrob Agents Chemother. 2015;59(6):3042\u201351.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"3301_CR53","doi-asserted-by":"publisher","first-page":"e01144","DOI":"10.1128\/aac.01144-22","volume":"67","author":"M Kunkel","year":"2023","unstructured":"Kunkel M, Doyle-Eisele M, Kuehl P, Rotermund K, Hittinger M, Ufer S, et al. Clofazimine inhalation suspension demonstrates promising toxicokinetics in canines for treating pulmonary nontuberculous mycobacteria infection. Antimicrob Agents Chemother. 2023;67(2):e01144-e1222.","journal-title":"Antimicrob Agents Chemother"}],"container-title":["AAPS PharmSciTech"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-025-03301-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12249-025-03301-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-025-03301-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T19:03:01Z","timestamp":1770318181000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12249-025-03301-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,9]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["3301"],"URL":"https:\/\/doi.org\/10.1208\/s12249-025-03301-6","relation":{},"ISSN":["1530-9932"],"issn-type":[{"value":"1530-9932","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,9]]},"assertion":[{"value":"8 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors report no conflicts of interest in the conduct of this research, preparation of this manuscript, or dissemination of results and findings.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"72"}}